MX2021001129A - Metodo de purificacion de antigenos. - Google Patents

Metodo de purificacion de antigenos.

Info

Publication number
MX2021001129A
MX2021001129A MX2021001129A MX2021001129A MX2021001129A MX 2021001129 A MX2021001129 A MX 2021001129A MX 2021001129 A MX2021001129 A MX 2021001129A MX 2021001129 A MX2021001129 A MX 2021001129A MX 2021001129 A MX2021001129 A MX 2021001129A
Authority
MX
Mexico
Prior art keywords
purification method
antigen purification
antigen
compositions
processes
Prior art date
Application number
MX2021001129A
Other languages
English (en)
Inventor
Kunal Bakshi
Marcin Krzysztof Bugno
Sumana Chandramouli
Matthew Albert Tyson
Zihao Wang
Mark Jonathan Wilson
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2021001129A publication Critical patent/MX2021001129A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan métodos, composiciones, procesos y usos relacionados con los polipéptidos recombinantes de proteína F soluble de RSV.
MX2021001129A 2018-07-31 2019-07-30 Metodo de purificacion de antigenos. MX2021001129A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862712280P 2018-07-31 2018-07-31
PCT/IB2019/056501 WO2020026147A1 (en) 2018-07-31 2019-07-30 Antigen purification method

Publications (1)

Publication Number Publication Date
MX2021001129A true MX2021001129A (es) 2021-07-02

Family

ID=68084873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001129A MX2021001129A (es) 2018-07-31 2019-07-30 Metodo de purificacion de antigenos.

Country Status (13)

Country Link
US (1) US20210292395A1 (es)
EP (1) EP3829618A1 (es)
JP (1) JP2021532764A (es)
KR (1) KR20210038919A (es)
CN (1) CN112566654A (es)
AU (1) AU2019313502A1 (es)
BR (1) BR112020027090A2 (es)
CA (1) CA3106304A1 (es)
EA (1) EA202190136A1 (es)
IL (1) IL280140A (es)
MX (1) MX2021001129A (es)
SG (1) SG11202100194VA (es)
WO (1) WO2020026147A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022023814A (ja) * 2020-07-27 2022-02-08 ファイザー・インク 組換え生産された三量体型のｒｓｖタンパク質の精製方法
JP2022023813A (ja) * 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
CN116621948B (zh) * 2023-07-21 2023-10-13 易康生物(苏州)有限公司 一种重组呼吸道合胞病毒f蛋白的纯化工艺方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
MY161412A (en) 2010-12-14 2017-04-14 Glaxosmithkline Biologicals Sa Mycobacterium antigenic composition
US10017543B2 (en) 2013-03-13 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CN115960263A (zh) * 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途

Also Published As

Publication number Publication date
IL280140A (en) 2021-03-01
JP2021532764A (ja) 2021-12-02
US20210292395A1 (en) 2021-09-23
BR112020027090A2 (pt) 2021-03-30
EA202190136A1 (ru) 2021-05-14
CA3106304A1 (en) 2020-02-06
KR20210038919A (ko) 2021-04-08
EP3829618A1 (en) 2021-06-09
CN112566654A (zh) 2021-03-26
AU2019313502A1 (en) 2021-01-28
WO2020026147A1 (en) 2020-02-06
SG11202100194VA (en) 2021-02-25

Similar Documents

Publication Publication Date Title
MX2021001129A (es) Metodo de purificacion de antigenos.
MX2023001403A (es) Neoantigenos y metodos de su uso.
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
MX2018014227A (es) Proteinas de union de cadena unica de fragmento variable cd3.
EA201791706A1 (ru) Связывающие icos белки
BR112017013981A2 (pt) receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
MX2016017311A (es) Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas.
MX2018011503A (es) Proteinas de union y metodos de uso de las mismas.
WO2018187356A3 (en) Protein antigens and uses thereof
WO2018178334A3 (fr) Purification des phycobiliproteines
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
WO2016073794A8 (en) Methods of producing two chain proteins in bacteria
MX2020003093A (es) Anticuerpos anti-cd19 novedosos.
MX2023005421A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
WO2017040329A3 (en) Peptides binding to bfl-1
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
NZ744289A (en) Composition containing amino acids
MX2018003445A (es) Expresion de proteinas que contienen fc.
MX2022003523A (es) Proteinas de union a antigenos.
SG11202107201YA (en) Process for producing, isolating, and purifying modified recombinant proteins
WO2019094669A3 (en) Self-assembling protein structures and components thereof
EP3581589A4 (en) HYBRID PEPTIDE, SET OF HYBRID PEPTIDES, COMPOSITION, USES OF THE HYBRID PEPTIDE, METHOD FOR INDUCING AN IMMUNE RESPONSE AND KITS
EA201892085A1 (ru) Новые белки, полученные из альфа-1-микроглобулина, и их применение
MX2022002774A (es) Método de captura y purificación de productos biológicos.